US FDA inspection successfully closed at Sellersville facility

Regulatory & Legal View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹168.00

prior close

₹173.18

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.6%+0.9% vs market

Pharmaceuticals peers, median of 166sector+0.9%+1.6% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Smallcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+0.8

15m

+0.8

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+1.6+0.9+0.9+1.6

Next day

+5.1+3.0+2.2+1.4+3.8

+3.5+3.3+0.2+1.7+1.8

+2.3+2.1+0.2+1.3+1.0

+2.1+2.8-0.7+1.5+0.6

+4.5+2.9+1.6+1.5+2.9

+6.8+2.4+4.3+1.2+5.6

15d

+17.1+1.4+15.7-0.6+17.8

+27.6+4.2+23.3+0.6+27.0

+30.0+4.7+25.3+2.7+27.3

+17.4-0.1+17.5-1.0+18.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma's manufacturing facility in Sellersville, USA has received an Establishment Inspection Report (EIR) from the US FDA, successfully closing the inspection that had begun earlier (per the company's May 10, 2026 update). A successful closure with an EIR indicates the facility meets US regulatory standards and can continue normal operations and US shipments without enforcement action.

Likely market impact

Positive for shareholders — a clean FDA inspection closure removes regulatory uncertainty and supports uninterrupted US market supplies from this facility.